Errors generated by a point-of-care CD4+ T-lymphocyte analyser: a retrospective observational study in nine countries

Emmanuel Fajardo, Carol Metcalf, Erwan Piriou, Monique Gueguen, David Maman, Pascale Chaillot, Vivian Cox, Maryam B Rumaney, Syanness Tunggal, Cara Kosack & Teri Roberts

Objective To estimate the proportion of invalid results generated by a CD4+ T-lymphocyte analyser used by Médecins Sans Frontières (MSF) in field projects and identify factors associated with invalid results.

Methods We collated 25 616 CD4+ T-lymphocyte test results from 39 sites in nine countries for the years 2011 to 2013. Information about the setting, user, training, sampling technique and device repair history were obtained by questionnaire. The analyser performs a series of checks to ensure that all steps of the analysis are completed successfully; if not, an invalid result is reported. We calculated the proportion of invalid results by device and by operator. Regression analyses were used to investigate factors associated with invalid results.

Findings There were 3354 invalid test results (13.1%) across 39 sites, for 58 Alere Pima devices and 180 operators. The median proportion of errors per device and operator was 12.7% (interquartile range, IQR: 10.3–19.9) and 12.1% (IQR: 7.1–19.2), respectively. The proportion of invalid results varied widely by country, setting, user and device. Errors were not associated with settings, user experience or the number of users per device. Tests performed on capillary blood samples were significantly less likely to generate errors compared to venous whole blood.

Conclusion The Alere Pima CD4+ analyser generated a high proportion of invalid test results, across different countries, settings and users. Most error codes could be attributed to the operator, but the exact causes proved difficult to identify. Invalid results need to be factored into the implementation and operational costs of routine CD4+ T-lymphocyte testing.

Introduction

The CD4+ T-lymphocyte count is the method recommended by the World Health Organization (WHO) to assess eligibility for antiretroviral treatment (ART). The CD4+ count also guides the clinical management of people living with human immunodeficiency virus (HIV). WHO recommends testing of viral load to detect treatment failure, but the CD4+ count continues to be used for ART monitoring if viral load cannot be tested. In settings where viral load can be determined, WHO suggests that routine CD4+ monitoring may be reduced or stopped for adults who are virologically stable.

Increased availability of ART has driven the establishment of laboratories analysing CD4+ count, but access to CD4+ testing requires adequate laboratory capacity and the means to transport specimens. Point-of-care CD4+ testing provides rapid results without the need to transport specimens and is considered an important tool to improve patient retention in care before treatment initiation.

The Alere Pima CD4+ analyser (Alere Technologies, Jena, Germany) was commercially launched in 2010. It is an automated analyser intended for counting CD4+ cells in capillary or venous whole blood within 20 minutes. The analyser is portable; can be operated with a rechargeable battery; contains Pima Bead cartridges are analysed daily for quality control.

The analyser has been extensively evaluated with favourable diagnostic performance at laboratory level and with acceptable results at clinic level, and in mobile clinics and in communities. Some studies showed higher variability of results at clinic level with capillary sampling. A recent meta-analysis showed that the analyser was comparable in performance to laboratory-based methods. The analyser identifies patients for treatment at the 350 CD4+ cells/µL threshold with a sensitivity of 91.6% and specificity of 94.8%.

In 2011, Médecins Sans Frontières (MSF) introduced the analyser in various projects to make CD4+ counting more accessible and to reduce loss to follow-up. During the implementation phase, several MSF sites reported a relatively high proportion of invalid results. Previous studies have reported invalid results ranging from 2% to 15%. However, these studies have been conducted under validation conditions and there is a lack of data describing errors under routine field conditions. Given the relatively high proportion of invalid results reported at MSF sites, we carried out a retrospective analysis of analyser data across a variety of settings. The objective of the study was to describe the proportion of CD4+ test errors and identify...
factors associated with these errors. We hypothesized that invalid results might be related to the experience of the operators or to the type of blood sample used.

Methods

Study population

We conducted a retrospective, observational, cross-sectional study using routine data from 39 MSF-supported sites using the analyser in the Central African Republic, the Democratic Republic of the Congo, Guinea, India, Kenya, Lesotho, Malawi, Mozambique and South Africa, between 1 January 2011 and 30 June 2013. Analysers were introduced in laboratories, primary health-care clinics, mobile clinics and in communities. HIV-positive individuals requiring ART eligibility assessment, and in some instances, ART monitoring, had CD4+ counts done on capillary or venous blood samples. The study protocol was submitted to the MSF ethics review board and exempted from ethics review because it complied with the standards for routinely collected data analyses.

Training

Laboratory technicians, clinicians and lay workers, were trained either by MSF-trained personnel or by the local Alere representative before use of the analyser. On-site training was conducted in half a day and focused on device operation, sampling technique, quality control and data management. In Lesotho and South Africa, a three-day centralized course in Alere’s training department in Cape Town was also provided to key staff who, in turn, trained multiple users on-site.

Sampling technique

Venous blood samples were used at all sites in the Central African Republic, the Democratic Republic of the Congo, Guinea, India, Kenya, Malawi and two sites in South Africa; capillary sampling was used in Lesotho, Mozambique and the remaining nine sites in South Africa. All sites in the Central African Republic, the Democratic Republic of the Congo, Guinea, India, Kenya and Malawi used a fixed volume micropipette to transfer 25 µL of venous blood to the cartridge. Two sites in South Africa used a plain capillary tube for cartridge filling. Capillary sampling was performed using the Alere recommended safety lancet (Sarstedt, Nümbrecht, Germany) at remaining sites in South Africa and all sites in Mozambique and Lesotho.

Quality control

Daily quality control was done at all sites using the manufacturer-supplied bead standards (with normal and low CD4+ cell counts) before testing patient samples. Eleven sites in South Africa were also enrolled in a regional proficiency testing programme and tested stabilized whole blood samples with normal or low CD4+ counts every two months. At most sites, dedicated paper-based registers were implemented to capture test results. None of the sites made use of the Alere online data portal during the study period. Test results and quality control data were analysed periodically in each country by a laboratory coordinator.

Data collection

Archived computer files containing CD4+ test results and quality control data were collated from each device. Information about the setting, user, training, sampling technique and device repair history were obtained by questionnaire, completed by the laboratory coordinator in each country. To ensure a representative number of tests per device and to eliminate errors due to inexperienced operators, we excluded data from devices with less than 50 tests, users performing less than 50 tests or unknown operators.

Analysis

We calculated the proportion of invalid CD4+ test results by device and by operator. Factors associated with invalid results were analysed using the binreg command in Stata version 13.0 (StataCorp. LP, College Station, United States of America). To determine the effects of user type and setting, we performed a series of analyses, restricted to those countries with comparable user type and setting.

We carried out the following comparisons: (i) tests done at clinics by lay workers versus tests done by clinicians in South Africa; (ii) tests done by laboratory technicians at clinics versus tests done at laboratories in the Central African Republic and the Democratic Republic of the Congo, and (iii) tests done by lay health workers in mobile

Table 1. Characteristics of participating sites, nine countries, 2011–2013

| Country                             | Sample type        | User type            | Settings                                  | Users, No. | Devices, No. | Tests, No. | Invalid tests, No. (%) |
|-------------------------------------|--------------------|----------------------|-------------------------------------------|------------|--------------|------------|------------------------|
| Central African Republic            | Venous blood       | Laboratory technician| 1 clinic, 1 laboratory                    | 10         | 3            | 1925       | 362 (18.8)            |
| Democratic Republic of the Congo    | Venous blood       | Laboratory technician| 2 laboratories, 2 clinics, 1 mobile clinic | 25         | 5            | 1888       | 254 (13.4)            |
| Guinea                              | Venous blood       | Laboratory technician| 2 clinics                                 | 10         | 2            | 1896       | 150 (7.9)             |
| India                               | Venous blood       | Laboratory technician| 2 clinics                                 | 5          | 2            | 1235       | 60 (4.9)              |
| Kenya                               | Venous blood       | Laboratory technician| 2 clinics, 2 laboratories, mobile clinics  | 26         | 11           | 5717       | 670 (11.7)            |
| Lesotho                             | Capillary blood    | Clinician, lay worker| 6 clinics, 3 mobile clinics               | 40         | 10           | 4434       | 681 (15.4)            |
| Malawi                              | Venous blood       | Clinician            | Mobile clinics                            | 10         | 7            | 1520       | 358 (23.6)            |
| Mozambique                          | Capillary blood    | Lay worker           | Mobile clinics                            | 6          | 2            | 1554       | 136 (8.8)             |
| South Africa                        | Venous, capillary  | Clinician, lay worker| 8 clinics, 3 mobile clinics               | 49         | 16           | 5447       | 683 (12.5)            |
| Total                               |                    |                      |                                           | 39         | 58           | 25616      | 3354 (13.1)           |

* Home-based testing.
settings versus tests done in clinics in Lesotho, Mozambique and South Africa. For each of these three comparisons, we calculated the frequency of errors stratified by country and tested for effect modification by country using the Mantel-Haenszel $\chi^2$ test. If there was no effect modification by country, we used generalized linear regression models to assess associations between error frequency and user type or setting. The $\chi^2$ test for categorical variables and the two-sample test of proportions were used to assess the significance of differences; a $P$-value of less than 0.05 was considered statistically significant.

**Results**

Between January 2011 and June 2013, there were 27,019 records in the data set. The exclusion criteria led to 1403 tests being removed, leaving 25,616 records from nine countries, across 39 sites, for 58 devices and 180 end-users. The characteristics of the participating sites are shown in Table 1. Most tests were done in fixed clinics (13,892; 54.2%), followed by home-based testing (5,913; 23.1%), mobile clinics (3,924; 15.3%) and laboratories (1,887; 7.4%). Tests were done by laboratory staff (8,230; 32.0%), clinicians (8,188; 32.0%) and lay workers (9,198; 36.0%). Most tests were done on venous blood (15,596; 61.0%) and the remainder on capillary blood (10,020; 39.0%). The median number of users per device was 3 (interquartile range, IQR: 2–5); the median number of tests per device was 470 (IQR: 252–672) and the median number of tests per user was 106 (IQR: 50–216).

**Invalid results**

There were 3,354 invalid results: (13.1%) overall; with 4.9% for India, 7.9% for Guinea, 8.8% for Mozambique, 11.7% for Kenya, 13.4% for the Democratic Republic of the Congo, 12.5% for South Africa, 15.4% for Lesotho, 18.8% for the Central African Republic and 23.6% for Malawi. There were 12.7% errors per device (IQR: 10.3–19.9) and 12.1% per user (IQR: 7.1–19.2).

**Source of errors**

The most common errors were code 850 (37.0%) and code 880 (18.0%). These errors can result from multiple causes (Fig. 1). Based on the error codes, the source of the error was the user (1542; 46.0%); user or device (1519; 45.3%);
device (83; 2.5%); or sample (147; 4.4%); with the remaining 63 errors (1.9%) being of unknown origin (Fig. 2). For calibration tests using Pima beads, 2% generated errors (207/10 404), with error codes 203 and 840 being the most common.

**Associated factors**

The factors associated with invalid tests are shown in Table 2. Compared to South Africa, invalid tests were lowest in India (risk ratio; RR: 0.36; 95% confidence interval, CI: 0.27–0.46) and highest in Malawi (RR: 1.72; 95% CI: 1.50–1.97). Compared to tests done in 2013, there were fewer invalid tests in 2011 and 2012, but there was no significant secular trend. Users were significantly more likely to experience invalid results within their first 50 tests, but once they had done 50 tests or more, there was no trend towards a lower frequency of invalid results as their level of experience increased further. The frequency of errors was not correlated with the number of users per device.

In clinics in South Africa, errors were significantly less frequent for lay health workers than clinicians (9.9% versus 19.8%; \( P = 0.001 \)). Among laboratory technicians, the association between setting and the frequency of invalid tests differed by country. In the Central African Republic, invalid tests among laboratory technicians were more frequent at the clinic than at the laboratory (22.4% versus 16.3%; \( P < 0.001 \)), while in the Democratic Republic of the Congo, invalid tests among laboratory technicians were less frequent at the clinic than at the laboratory (13.2% versus 18.7%; \( P < 0.001 \)). Among lay health workers in Lesotho, Mozambique and South Africa, the association between setting and the frequency of invalid tests differed by country: in South Africa and Lesotho, the frequency of invalid tests was comparable in mobile clinic and fixed clinic settings (9.0% versus 9.9% in South Africa; \( P = 0.35 \)); and 15.5% versus 16.1% in Lesotho; \( P = 0.66 \). However, in Mozambique, the frequency of invalid tests in mobile clinics was considerably lower than in fixed clinics (4.1% versus 13.6%; \( P < 0.001 \)).

**Blood sample type**

There were fewer invalid results when capillary blood samples were used (12.0%, versus 14.0% for venous blood samples; \( P < 0.001 \)). In a subgroup multivariate analysis restricted to South Africa, (the only country in which both sample types were used) this association was strengthened (RR: 0.46; 95% CI: 0.40–0.53).

### Discussion

Under routine field conditions, the proportion of invalid CD4+ test results ranged from 5% in India to 24% in Malawi. Previous studies have reported comparable ratios from 5% in Thailand to 19% in South Africa. \(^{3,13}\) In our study, invalid results were slightly more frequent in venous blood samples than capillary blood samples. The use of a pipette to fill the device cartridge may generate air bubbles; since the CD4+ test is based on image detection, the presence of air bubbles may affect the results. To decrease the generation of air bubbles, the manufacturer recommends that capillary tubes instead of pipettes be used to transfer venous blood to the device. Studies in Senegal and Uganda reported more errors using capillary blood specimens (14% and 18%) compared to venous blood specimens (5% and 8%). \(^{3,14,15}\) However, other studies using venous blood have also found high ratios of invalid results: 10% in Ethiopia, 11% in USA and 15% in South Africa. \(^{16,17,18}\) Some studies have shown an increased variability of Alere Pima CD4+ results when capillary blood is used. \(^{3,14,16}\) However, a recent systematic review and meta-analysis found that capillary blood yielded more accurate results than venous blood. \(^{19}\) The fact that errors were more likely to occur using venous blood in our study may be related to the pipetting skills of laboratory staff. Therefore, training of laboratory staff in pipetting skills is as important as training clinic staff to perform capillary bleeds required for field testing.

The proportion of invalid samples for calibration tests was low (2%); however, in some instances, operators did not know how to interpret the results.
so that testing continued despite clear indication of a problem; this calls for retraining. Multiple factors probably contribute to the wide variability of invalid results among countries, sites, devices and operators in our study. We did not find a clear association between the number of operators per device, the type of operator or the setting. Prospective studies under field conditions, specifically designed to evaluate the effect of various factors on the invalid tests are needed.

There were several limitations resulting from the retrospective nature of our study. We could not analyse errors according to cartridge lot number because this information was not contained in the cartridge barcode and sites did not document lot numbers systematically. It proved impossible to identify lot numbers via orders, as they were placed through various procurement centres in Europe as well as purchased from local distributors. We were unable to link results of repeat testing due to errors, so it was not possible to estimate the proportion of valid or invalid results after a second test. During the study period, none of the sites made use of online data systems for the analyser. Remote analysers can be connected to a centralised data warehouse via the internet, which could improve the timeliness of monitoring.

The high proportion of invalid CD4+ test results, necessitating the use of a second cartridge, raises the cost of testing per patient. Overall, 3354 tests had to be repeated; at a current price of 6 United States dollars (US$) per test, this translates to a cost of US$ 20 124. Repeat tests take time to process, decrease throughput, and oblige the patient to provide another blood sample if capillary sampling is used.

Training, monitoring, quality assessment and troubleshooting are essential aspects of point-of-care testing. It is important that post-market surveillance is done regularly and manufacturers continue to make the necessary improvements to their technologies and to supply service, maintenance and training for the full lifespan of the device.

In conclusion, 13.1% of results from the Alere Pima CD4+ analyser were invalid in this study. Most errors could be attributed to the operator but elucidating the exact cause proved to be difficult. Analyser errors are frequent and need to be factored into the implementation and operational cost for routine CD4+ testing.

Acknowledgements
We thank the MSF Laboratory Working Group, the staff in the nine projects, Ralph Labugger (Alere, Germany) and Greg Khoury (Alere, South Africa).

Funding: This study was funded by Médecins Sans Frontières, Operational Centre Brussels, Belgium.

Competing interests: None declared.

MLC

CD4+ analysis

Drug resistance can now be tested in a number of countries across the globe. The Alere Pima CD4+ analyser was specifically designed to evaluate the performance of the Alere Pima CD4+ analyser in the field. We were unable to link results of repeat testing due to errors, so it was not possible to estimate the proportion of valid or invalid results after a second test. During the study period, none of the sites made use of online data systems for the analyser. Remote analysers can be connected to a centralised data warehouse via the internet, which could improve the timeliness of monitoring.

The high proportion of invalid CD4+ test results, necessitating the use of a second cartridge, raises the cost of testing per patient. Overall, 3354 tests had to be repeated; at a current price of 6 United States dollars (US$) per test, this translates to a cost of US$ 20 124. Repeat tests take time to process, decrease throughput, and oblige the patient to provide another blood sample if capillary sampling is used.

Training, monitoring, quality assessment and troubleshooting are essential aspects of point-of-care testing. It is important that post-market surveillance is done regularly and manufacturers continue to make the necessary improvements to their technologies and to supply service, maintenance and training for the full lifespan of the device.

In conclusion, 13.1% of results from the Alere Pima CD4+ analyser were invalid in this study. Most errors could be attributed to the operator but elucidating the exact cause proved to be difficult. Analyser errors are frequent and need to be factored into the implementation and operational cost for routine CD4+ testing.

Acknowledgements
We thank the MSF Laboratory Working Group, the staff in the nine projects, Ralph Labugger (Alere, Germany) and Greg Khoury (Alere, South Africa).

Funding: This study was funded by Médecins Sans Frontières, Operational Centre Brussels, Belgium.

Competing interests: None declared.

MLC

CD4+ analysis

Drug resistance can now be tested in a number of countries across the globe. The Alere Pima CD4+ analyser was specifically designed to evaluate the performance of the Alere Pima CD4+ analyser in the field. We were unable to link results of repeat testing due to errors, so it was not possible to estimate the proportion of valid or invalid results after a second test. During the study period, none of the sites made use of online data systems for the analyser. Remote analysers can be connected to a centralised data warehouse via the internet, which could improve the timeliness of monitoring.

The high proportion of invalid CD4+ test results, necessitating the use of a second cartridge, raises the cost of testing per patient. Overall, 3354 tests had to be repeated; at a current price of 6 United States dollars (US$) per test, this translates to a cost of US$ 20 124. Repeat tests take time to process, decrease throughput, and oblige the patient to provide another blood sample if capillary sampling is used.

Training, monitoring, quality assessment and troubleshooting are essential aspects of point-of-care testing. It is important that post-market surveillance is done regularly and manufacturers continue to make the necessary improvements to their technologies and to supply service, maintenance and training for the full lifespan of the device.

In conclusion, 13.1% of results from the Alere Pima CD4+ analyser were invalid in this study. Most errors could be attributed to the operator but elucidating the exact cause proved to be difficult. Analyser errors are frequent and need to be factored into the implementation and operational cost for routine CD4+ testing.

Acknowledgements
We thank the MSF Laboratory Working Group, the staff in the nine projects, Ralph Labugger (Alere, Germany) and Greg Khoury (Alere, South Africa).

Funding: This study was funded by Médecins Sans Frontières, Operational Centre Brussels, Belgium.

Competing interests: None declared.
Erreurs générées par l’analyseur de lymphocytes T CD4+ sur le lieu d’intervention: une étude rétrospective par observation dans neuf pays

Objectif Estimer la proportion de résultats non valides générés par l’analyseur de lymphocytes T CD4+ utilisé par Médecins Sans Frontières (MSF) dans les projets de terrain et déterminer les facteurs associés aux résultats non valides.

Méthodes Nous avons rassemblé 25 616 résultats de tests des lymphocytes T CD4+ réalisés sur 39 sites dans neuf pays entre 2011 et 2013. Un questionnaire a permis d’obtenir des informations sur le lieu, l’utilisateur, la formation, la méthode d’échantillonnage et les réparations effectuées sur l’appareil. L’analyseur réalise une série de contrôles afin de garantir que toutes les étapes de l’analyse se déroulent correctement; si ce n’est pas le cas, il indique un résultat non valide. Nous avons calculé la proportion de résultats non valides par appareil et par opérateur. Des analyses de régression ont permis de rechercher les facteurs associés aux résultats non valides.

Résultats Nous avons relevé 3354 résultats de tests non valides (13,1%) sur les 39 sites, avec 58 appareils Alere Pima™ et 180 opérateurs. La proportion moyenne d’erreurs par appareil et par opérateur était respectivement de 12,7% (intervalle interquartile, IQR: 10,3–19,9) et de 12,1% (IQR: 7,1–19,2). La proportion de résultats non valides variait considérablement en fonction du pays, du lieu, de l’utilisateur et de l’appareil. Les erreurs n’étaient pas associées aux lieux, à l’expérience de l’utilisateur ou au nombre d’utilisateurs par appareil. Les tests effectués sur des prélèvements de sang capillaire étaient nettement moins susceptibles de générer des erreurs que ceux réalisés sur du sang veineux total.

Conclusion L’analyseur de CD4+ Alere Pima a généré une proportion élevée de résultats non valides, dans différents pays, différents lieux et avec différents utilisateurs. La plupart des codes d’erreur ont pu être imputés à l’opérateur, mais les causes exactes se sont avérées difficiles à déterminer. Les résultats non valides doivent être pris en compte dans les coûts de mise en œuvre et d’exploitation des tests de routine des lymphocytes T CD4+.

Résumé

La proportion moyenne d’erreurs par appareil et par opérateur était respectivement de 12,7% (intervalle interquartile, IQR: 10,3–19,9) et de 12,1% (IQR: 7,1–19,2). La proportion de résultats non valides variait considérablement en fonction du pays, du lieu, de l’utilisateur et de l’appareil. Les erreurs n’étaient pas associées aux lieux, à l’expérience de l’utilisateur ou au nombre d’utilisateurs par appareil. Les tests effectués sur des prélèvements de sang capillaire étaient nettement moins susceptibles de générer des erreurs que ceux réalisés sur du sang veineux total.

Conclusion L’analyseur de CD4+ Alere Pima a généré une proportion élevée de résultats non valides, dans différents pays, différents lieux et avec différents utilisateurs. La plupart des codes d’erreur ont pu être imputés à l’opérateur, mais les causes exactes se sont avérées difficiles à déterminer. Les résultats non valides doivent être pris en compte dans les coûts de mise en œuvre et d’exploitation des tests de routine des lymphocytes T CD4+.
Resumen

Errores generados por un analizador de linfocitos en el punto de atención CD4+: un estudio observacional retrospectivo en nueve países

Objetivo
Estimar la proporción de resultados no válidos generados por un analizador de linfocitos CD4+ T utilizado por Médicos sin Fronteras (MSF) en proyectos de campo e identificar los factores asociados a los resultados no válidos.

Métodos
Se recopilaron 25 616 resultados de pruebas de linfocitos CD4+ T de 39 localizaciones en nueve países entre los años 2011 y 2013. La información sobre el entorno, los usuarios, la formación, la técnica de muestreo y el historial de reparación del dispositivo se obtuvo a través de un cuestionario. El analizador lleva a cabo una serie de chequeos para asegurar que se completan con éxito todos los pasos del análisis; si no es así, se informa de un resultado no válido. Se calculó la proporción de resultados no válidos por dispositivo y operador. Se utilizaron análisis de regresión para investigar los factores asociados con los resultados no válidos.

Resultados
Hubo 3354 resultados no válidos de pruebas (13,1%) en 39 localizaciones, para 58 dispositivos Alere Pima™ y 180 operadores. La proporción media de errores por dispositivo y operador fue del 12,7% (rango intercuartílico, RIC: 10,3–19,9) y del 12,1% (RIC: 7,1–19,2), respectivamente. La proporción de resultados no válidos varió ampliamente entre países, entornos, usuarios y dispositivos. Los errores no estaban asociados con los entornos, la experiencia del usuario o el número de usuarios por dispositivo. Las pruebas realizadas con muestras de sangre capilar tenían menos posibilidades de generar error que las realizadas con sangre entera venosa.

Conclusión
El analizador Alere Pima CD4+ generó una alta proporción de resultados no válidos de pruebas en diferentes países, entornos y usuarios. La mayoría de los códigos de error podrían atribuirse al operador, pero resultó difícil identificar las causas exactas. Los resultados no válidos de las pruebas rutinarias de linfocitos CD4+ T deberán tenerse en cuenta en la aplicación y los costes operacionales.

Referencias
23. Zeh C, Inzaile SC, Otieno F, Dyaro B, Ndlovu R, Rose CE, et al. Evaluation of Pima CD4+ point-of-care device in western Kenya for potential use in field settings [Abstract #34M]. In: Proceedings of the 21st Conference on Retroviruses and Opportunistic Infections; 2014 Mar 3–6; Boston, USA. Atlanta: Centers for Disease Control and Prevention; 2014. Available from: http://www.croiconference.org/sites/allabstracts/624.pdf [cited 2015 May 27].

24. Mala J, Manak M, Lombardi K, Crawford K, Giese R, Bryant M, et al. Clinical evaluation of PIMA point of care assay for evaluation of CD4+ cell counts [Poster #THPRD1121]. In: Proceedings of 20th International AIDS Conference; 2014 Jul 20–25; Melbourne, Australia. Geneva: International AIDS Society; 2014. Available from: http://pag.aids2014.org/Abstracts.aspx?AID=2067

25. Collino Perez CG, Gallego Gonzalez F. Evaluación metodológica del equipamiento pima para la cuantificación de linfocitos T CD4+. Argentina: Ministerio de Salud de la Provincia de Córdoba; 2014. Available from: https://www.academia.edu/11400645/EvaluacionMetodologicaDelEquipamiento_PIMA_PARA_LA_CUANTIFICACIONDECD4_315Mayo2014 [cited 2015 May 27]. Spanish.

26. Mtapi-Zinyowera S, Chiderne M, Mangwanya D, Mugurungi O, Guduleya S, Hatzold K, et al. Evaluation of the PIMA point-of-care CD4 analyzer in VCT clinics in Zimbabwe. J Acquir Immune Defic Syndr. 2010 Sep 15;55(1):1–7. doi: http://dx.doi.org/10.1097/QAI.0b013e3181e93071 PMID: 20622679

27. Jani IV, Sitele NE, Chongo PL, Alfai ER, Quevedo JI, Tobaiwa O, et al. Accurate CD4 T-cell enumeration and antiretroviral drug toxicity monitoring in primary healthcare clinics using point of care testing. AIDS. 2011 Mar 27;25(6):807–12. doi: http://dx.doi.org/10.1097/QAD.0b013e32834f4224 PMID: 21378335

28. Mnyani CN, McIntyre JA, Myer L. The reliability of point-of-care CD4 testing in identifying HIV-infected pregnant women eligible for antiretroviral therapy. J Acquir Immune Defic Syndr. 2012 Jul 16;60(1):260–4. doi: http://dx.doi.org/10.1097/QAI.0b013e318256b651 PMID: 22487389

29. Thakar M, Mahajan B, Shaikh N, Bagwan S, Sane S, Kabra S, et al. Utility of the point of care CD4 analyzer, PIMA, to enumerate CD4 counts in the field settings in India. AIDS Res Ther. 2012;9(1):26. doi: http://dx.doi.org/10.1186/1742-6405-9-26 PMID: 22998738

30. Herbert S, Edwards S, Carrick G, Copas A, Sandford C, Amphlett M, et al. Evaluation of PIMA point-of-care CD4 testing in a large UK HIV service. Sex Transm Infect. 2012 Oct;88(6):413–7. doi: http://dx.doi.org/10.1136/sextrans-2012-050507 PMID: 22543320

31. Manabe YC, Wang Y, Elbireer A, Auerbach B, Castelnuevo B. Evaluation of portable point-of-care CD4 counter with high sensitivity for detecting patients eligible for antiretroviral therapy. PLoS ONE. 2012;7(4):e34319. doi: http://dx.doi.org/10.1371/journal.pone.003443 PMID: 22536323

32. Myer L, Daskilewicz K, McIntyre J, Bekker LG. Comparison of point-of-care versus laboratory-based CD4 cell enumeration in HIV-positive pregnant women. J Int AIDS Soc. 2013;16(1):1869. doi: http://dx.doi.org/10.7448/IAS.16.1.1869 PMID: 24044627

33. Gous N, Scott L, Potgieter J, Ntabeni L, Enslin S, Newman R, et al. Feasibility of performing multiple point of care testing for HIV anti-retroviral treatment uptake and linkage to care in a novel program of home-based HIV counseling and testing with facilitated referral in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):e1–8. doi: http://dx.doi.org/10.1097/QAI.0b013e318219bb567 PMID: 23714740

34. Malagun M, Nano G, Chevallier C, Ipina R, Sawiya G, Kivavia J, et al. Multisite evaluation of point of care CD4 testing in Papua New Guinea. PLoS ONE. 2012;7(11):e12173. doi: http://dx.doi.org/10.1371/journal.pone.0121713 PMID: 22542610

35. Malagun M, Nano G, Chevallier C, Opina R, Sawiya G, Kivavia J, et al. Multisite evaluation of point of care CD4 testing in Papua New Guinea. PLoS ONE. 2014;9(11):e112173. doi: http://dx.doi.org/10.1371/journal.pone.0112173 PMID: 25197773

36. Galiwango RM, Lubyayi L, Musoke R, Kalibbala S, Buwembo M, Kasule J, et al. Field evaluation of PIMA point-of-care CD4 testing in Rakai, Uganda. PLoS ONE. 2014;9(5):e88928. doi: http://dx.doi.org/10.1371/journal.pone.0088928 PMID: 24614083